Interferon-Alpha May Delay Full Onset of Type 1 Diabetes

Results of a phase 2 trial indicate that a low dose of oral interferon-alpha may, for a period, preserve beta cell function in newly diagnosed type 1 diabetes (formerly juvenile diabetes). "It shows a strong trend in preserving insulin-producing beta cell function that is significantly better than placebo," said Dr. Staley Brod, principal investigator of the trial, which includes the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "It can extend the 'honeymoon phase' of the disease, allowing the body to still produce insulin from beta cells, which correlates with decreased complication rates." A honeymoon phase sometimes occurs just after diagnosis as the body tries to rebound. Many patients experience a period when their need for insulin becomes minimal, control of blood sugar improves and beta cells partially recover. If the pancreas is still able to function, the highs and lows experienced by taking manufactured insulin can be decreased. The results of the phase 2 trial were published in the July issue of Diabetes Care. [Press release] [Diabetes Care abstract]
Login Or Register To Read Full Story